ScreenerHero

AGENAgenus Inc.

NAS · US · Healthcare · Biotechnology · agenusbio.com
8.090USD-2.06%Mkt Cap: 364.13M $P/E: 2.71

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap364.13M $
Enterprise Value352.40M $
Revenue (TTM)132.69M $
Gross Profit33.84M $
Net Income (TTM)115.00K $
Revenue/Share3.645 USD
Last Price8.090 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees81
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS00847G7051
Valuation
P/E (Trailing)2.71
P/E (Forward)-124.83
PEG1.44
EV/EBITDA8.68
EV/Revenue2.66
P/S2.54
P/B-1.60
EPS (TTM)2.71
EPS (Forward)-0.06
52W Range
2.71088% of range8.840
52W High8.840 USD
52W Low2.710 USD
Profitability
Gross Margin29.63%
Oper. Margin32.72%
EBITDA Margin30.60%
Profit Margin0.10%
ROE-0.04%
ROA0.05%
Growth
Revenue Growth34.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.19M $
CapEx (TTM)6.00K $
FCF Margin-56.36%
FCF Yield-20.54%
Net Debt21.97M $
Net Debt/EBITDA0.54
Balance Sheet
Debt/Equity-0.21
Current Ratio0.34
Quick Ratio0.32
Book Value/Sh-4.6710 USD
Cash/Share0.4160 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateApr 12, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)19.50 USD
Upside (mean)+141.0%
Target Range14.00 USD – 25.00 USD
$14.00+141.0% to mean$25.00
# Analysts2
Ownership
Shares Out.45.01M
Float40.24M
Insiders6.23%
Institutions45.95%
Short Interest
Short Ratio0.7d
Short % Float14.01%
Short % Out.13.85%
Shares Short6.23M
Short (prev mo.)5.99M
Technical
SMA 505.196 (+55.7%)
SMA 2004.013 (+101.6%)
Beta1.40
S&P 52W Chg18.16%
Avg Vol (30d)7.79M
Avg Vol (10d)1.32M
Technical Indicators
RSI (14)66.5
MACD0.7161
MACD Signal0.7592
MACD Hist.-0.0431
BB Upper8.587 USD
BB Middle7.192 USD
BB Lower5.797 USD
BB Width38.79%
ATR (14)0.7087 USD
Vol Ratio (20d)0.91x